PDE4

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

Retrieved on: 
星期二, 四月 23, 2024
Ulcerative colitis, CMO, Science, Strand Life Sciences, Machine learning, Partnership, PDE4, Therapy, Data, Patient, Biomarker, Medicine, Autoimmunity, UC

Carlsbad, CA, April 23, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has entered into a transformative strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.

Key Points: 
  • The collaboration with Strand Life Sciences provides Palisade Bio access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors.
  • "Our partnership with Strand Life Sciences signifies a pivotal advancement in our mission to revolutionize UC treatment," said Dr. Mitch Jones, CMO at Palisade Bio.
  • "We are thrilled to collaborate with Palisade Bio in this transformative endeavor toward advancing precision medicine for ulcerative colitis therapy," added Ramesh Hariharan, CEO at Strand Life Sciences.
  • Palisade Bio is committed to advancing precision medicine solutions for UC and other inflammatory indications.

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Retrieved on: 
星期二, 四月 16, 2024
LC-MS, Therapy, CMO, Patient, PDE4, Autoimmunity, UC, Fine chemical

Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

Key Points: 
  • These findings demonstrated that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.
  • The enzymatic activity in stool samples was assessed using LC-MS analysis with all stool samples meeting the target conversion rate within a 24-hour period.
  • The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.
  • "The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC," said Dr. Mitch Jones, CMO at Palisade Bio.

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™

Retrieved on: 
星期三, 四月 10, 2024
Trial of the century, Publication, PDE4, IBD, Therapy, Patient, Autoimmunity, UC, Pharmaceutical industry

Carlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it presented at IBD Innovate: Product Development for Crohn’s & Colitis™ held April 9-10, 2024 in Cambridge, MA. As part of the conference, Christophe Mellon, Chief Executive Officer of Giiant Pharma, Inc., the Company’s research partner, and Dr. Mitch Jones, Chief Medical Officer of Palisade Bio gave an oral presentation titled, “Advancing PALI-2108: Discovery to Strategy Positioning,” which discussed the development of PALI-2108, its differentiation and positioning in the competitive landscape as well as a clinical pathway towards late-stage development. The presentation is accessible on the Publications page under the Science section of Palisade Bio’s website, www.palisadebio.com. “We were pleased to participate with Giiant at the premier IBD conference and provide further information on PALI-2108. We continue to generate a growing body of data from PALI-2108 for the treatment of UC and remain on track to launch our Phase 1 clinical study later this year," commented Dr. Jones.

Key Points: 
  • The presentation is accessible on the Publications page under the Science section of Palisade Bio’s website, www.palisadebio.com .
  • “We were pleased to participate with Giiant at the premier IBD conference and provide further information on PALI-2108.
  • As previously announced, the development of PALI-2108 is supported by a $500,000 research program funding agreement with Giiant from the US Crohn’s and Colitis Foundation, through its IBD Ventures program.
  • PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia

Retrieved on: 
星期二, 四月 23, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Volunteering, CIAS, TDS, Safety, Pharmacokinetics, Neuroscience, Partnership, PDE4, Schizophrenia, Therapy, Patient, Multimedia, AUC, Absorption, Plasma, Deficit spending, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS).

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS).
  • (Graphic: Alto Neuroscience, Inc.)
    “These positive results provide a strong indication that ALTO-101 could become an important therapeutic option for a broad range of indications,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience.
  • “Oral PDE4 inhibitors have shown promise as pro-cognitive therapeutics but are associated with burdensome and dose-limiting side effects.
  • Despite these dosing and tolerability challenges, PDE4 inhibitors are used widely in other non-CNS indications, often with sub-optimal dosing regimens.

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期三, 三月 27, 2024
Research, Ulcerative colitis, Exercise, Initiate, Average cost, Patient, Internet, UC, PDE4, Insurance, Trial of the century, IBD, Medicine, Completeness, Inflammatory bowel disease, Therapy, FDA, Autoimmunity, Physician, Consultant, Pharmaceutical industry

Carlsbad, CA, March 27, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the full year 2023 and provided a corporate update.

Key Points: 
  • “2023 was a transformative year for Palisade Bio as we strategically shifted into the autoimmune, inflammatory, and fibrotic disease space, with the focus on our precision medicine approach in inflammatory bowel disease,” commented J.D.
  • “As a result of the progress made by our development team, we are on track to launch the Phase 1 study of PALI-2108 by the end of 2024.
  • Summary of Financial Results for the Year Ended December 31, 2023
    As of December 31, 2023, the Company had cash, cash equivalents and restricted cash of $12.5 million.
  • Net operating loss was $13.1 million for the year ended December 31, 2023 compared to $15.7 million for the year ended December 31, 2022.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
星期四, 三月 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Shaperon Enrolls Its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'

Retrieved on: 
星期一, 三月 18, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Growth, Atopic dermatitis, Inflammation, Patient, EASI, Technology transfer, PDE4, IND, Patent, FDA, Steroid, JAK, Pharmaceutical industry

Shaperon, Inc. (Kosdaq: 378800), a biotechnology company developing innovative immune drugs, announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis.

Key Points: 
  • Shaperon, Inc. (Kosdaq: 378800), a biotechnology company developing innovative immune drugs, announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis.
  • Employing a rigorous double-blind, placebo-controlled methodology, the trial is anticipated to conclude by the first half of 2026.
  • Market research forecasts indicate a robust growth of over 8.7%, projecting the global atopic dermatitis market to reach $19.1 billion by 2030.
  • Nugel represents a paradigm shift in atopic dermatitis therapy as the world's first inflammation control drug targeting 'GPCR19' action.

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Retrieved on: 
星期三, 二月 28, 2024
Psoriasis, Atopic dermatitis, Dermatitis, Skin, PDE4, Patient, Satō, Itch, Partnership

“We are delighted to partner with Sato, who share our mission to provide meaningful innovation to individuals suffering from immune-mediated skin diseases.

Key Points: 
  • “We are delighted to partner with Sato, who share our mission to provide meaningful innovation to individuals suffering from immune-mediated skin diseases.
  • Topical roflumilast has been shown to effectively clear skin and reduce itch, with a safe and well-tolerated profile.
  • With this collaboration, we believe we can make an impact for individuals suffering from immune-mediated skin diseases in Japan,” said Seiichi Sato, president and chief executive officer, Sato.
  • Sato will be responsible for development, manufacturing, and commercialization of roflumilast cream and roflumilast foam and other topical roflumilast presentations in Japan.

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期二, 二月 27, 2024
Janus, Acquisition, Week, Psoriasis, GTN, Research, Health Canada, Investment, Inflammation, FDA, Marketing, Atopic dermatitis, Food, Dermatitis, Growth, Shanda, Patent, JAK1, PDUFA, Pharmacy benefit management, PDE4, Alopecia areata, Food and Drug Administration, Webcast, Half-life, Disease, SLR, Itch, NDA, Prescription, Scalp, Pharmaceutical industry

The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.

Key Points: 
  • The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.
  • Total revenues for the quarter ended December 31, 2023 were $13.5 million compared to $3.0 million for the corresponding period in 2022.
  • Net cash used in operating activities was $56.2 during the fourth quarter and $247.1 million during the full year 2023.
  • Arcutis management will host a conference call and webcast today at 8:30 am ET to discuss the financial results for the quarter and year and provide a business update.

Phosphodiesterase-4 (PDE4) Inhibitor Market to Witness Significant Growth by 2034 Driven by In-depth Industry Analysis and Forecast - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 5, 2024
Biotechnology, Pharmaceutical, Health, Therapy, Competitive landscape, Research, Internet, Intelligence, SWOT, PDE4, Human, Biomarker, Patient, Pharmaceutical industry

The "Phosphodiesterase-4 (PDE4) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Phosphodiesterase-4 (PDE4) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • Research into the Phosphodiesterase-4 (PDE4) Inhibitor market reveals critical insights into its expected evolution through the year 2034.
  • A market outlook sheds light on how these developments could influence market dynamics, juxtaposing current therapies with their next-generation counterparts.
  • The comprehensive report arms industry professionals with the requisite intelligence to anticipate the trajectory of the PDE4 Inhibitor market.